CL2A is primarily used in the development of antibody-drug conjugates (ADCs) for targeted cancer therapy. Its high potency as a cytotoxic agent allows for effective tumor cell killing when delivered selectively via monoclonal antibodies. Due to its mechanism of action involving DNA cross-linking, CL2A induces apoptosis in rapidly dividing cancer cells. It is especially valued in ADC design for its stability in circulation and efficient release within cancer cells, minimizing off-target effects. This makes it suitable for treating solid tumors and hematological malignancies where precision and potency are critical.